Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical
KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling
Globe Newswire21-02-2023, 13:07
ATN Reports Fourth-Quarter and Full-Year 2022 Results; 23-02-2023, 04:40